Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Account Payables: 2013-2025

Historic Change in Account Payables for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $538,000.

  • Theravance Biopharma's Change in Account Payables rose 344.55% to $538,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $759,000, marking a year-over-year increase of 296.63%. This contributed to the annual value of $750,000 for FY2024, which is 12400.00% up from last year.
  • As of Q3 2025, Theravance Biopharma's Change in Account Payables stood at $538,000, which was up 173.40% from -$733,000 recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Change in Account Payables peaked at $5.1 million during Q2 2021, and registered a low of -$5.7 million during Q4 2021.
  • In the last 3 years, Theravance Biopharma's Change in Account Payables had a median value of $166,000 in 2025 and averaged $66,091.
  • Data for Theravance Biopharma's Change in Account Payables shows a peak YoY increase of 344.55% (in 2025) and a maximum YoY decrease of 36,550.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Change in Account Payables stood at -$5.7 million in 2021, then spiked by 34.46% to -$3.8 million in 2022, then surged by 90.75% to -$348,000 in 2023, then surged by 326.44% to $788,000 in 2024, then surged by 344.55% to $538,000 in 2025.
  • Its Change in Account Payables stands at $538,000 for Q3 2025, versus -$733,000 for Q2 2025 and $166,000 for Q1 2025.